Interactive Financial Charts Not Available

Biosenic SA (BIOS) | Financial Analysis & Statements

Biosenic SA | Small-cap | Healthcare

€0.00

0.00%

Biosenic SA vs Argenx SE Biosenic SA vs UCB S.A Biosenic SA vs European Medical Biosenic SA vs Celyad Oncology S.A Biosenic SA vs Onward Medical N.V Biosenic SA vs BEL 20 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Dec 2014

Income Metrics

Revenue 0

Operating Income -1.9M

Net Income -1.9M

Balance Sheet Metrics

Total Assets 9.3M

Total Liabilities 29.8M

Shareholders Equity -20.4M

Cash Flow Metrics

Operating Cash Flow -3.2M

Free Cash Flow -260.0K

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Biosenic SA Income Statement From 2019 to 2023

Metric	2023	2022	2021	2020	2019
Revenue i	0	0	0	1.0M	0
Cost of Goods Sold i	-	-	-	-	-
Gross Profit i	-	-	-	-	-
Gross Margin % i	0.0%	0.0%	0.0%	0.0%	0.0%
Operating Expenses
Research & Development i	3.9M	1.0M	619.0K	15.4M	7.5M
Selling, General & Administrative i	1.8M	693.0K	265.0K	1.8M	1.5M
Other Operating Expenses i	184.0K	272.0K	84.0K	-	-
Total Operating Expenses i	6.0M	2.0M	968.0K	17.2M	9.0M
Operating Income i	-7.0M	-2.3M	-878.0K	-15.0M	-7.9M
Operating Margin % i	0.0%	0.0%	0.0%	-1,501.7%	0.0%
Non-Operating Items
Interest Income i	57.0K	3.0K	0	24.0K	17.0K
Interest Expense i	1.5M	278.0K	62.0K	678.0K	261.0K
Other Non-Operating Income	-	-	-	-	-
Pre-tax Income i	-29.0M	-3.0M	-984.0K	-15.8M	-7.5M
Income Tax i	-7.0K	0	0	78.0K	0
Effective Tax Rate % i	0.0%	0.0%	0.0%	0.0%	0.0%
Net Income i	-29.0M	-3.0M	-984.0K	-11.9M	-10.3M
Net Margin % i	0.0%	0.0%	0.0%	-1,194.0%	0.0%
Key Metrics
EBITDA i	-8.0M	-2.3M	-909.0K	-14.5M	-6.2M
EPS (Basic) i	€-0.21	€-0.02	€-14.89	€-1.02	€-1.08
EPS (Diluted) i	€-0.21	€-0.02	€-14.89	€-1.02	€-1.08
Basic Shares Outstanding i	136932018	120132013	66389	11723182	9538538
Diluted Shares Outstanding i	136932018	120132013	66389	11723182	9538538

Income Statement Trend

Biosenic SA Balance Sheet From 2019 to 2023

Metric	2023	2022	2021	2020	2019
Assets
Current Assets
Cash & Equivalents i	117.0K	1.8M	759.0K	14.6M	8.6M
Short-term Investments i	-	-	1.2M	-	-
Accounts Receivable i	153.0K	1.0M	0	1.1M	132.0K
Inventory i	-	-	-	-	-
Other Current Assets	273.0K	290.0K	4.0K	328.0K	74.0K
Total Current Assets i	1.8M	4.6M	1.1M	18.8M	11.7M
Non-Current Assets
Property, Plant & Equipment i	56.0K	50.0K	13.0K	2.3M	3.4M
Goodwill i	3.0M	20.9M	0	28.0K	28.0K
Intangible Assets i	3.0M	17.3M	23.0K	28.0K	28.0K
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	137.0K	135.0K	-13.0K	1.3M	1.0K
Total Non-Current Assets i	7.7M	24.7M	38.0K	6.0M	10.7M
Total Assets i	9.6M	29.3M	1.2M	24.8M	22.4M
Liabilities
Current Liabilities
Accounts Payable i	3.6M	2.0M	92.0K	5.2M	3.1M
Short-term Debt i	11.8M	8.0M	1.2M	3.1M	2.7M
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	49.0K	-2.0K	-3.0K	-	-
Total Current Liabilities i	15.8M	10.4M	1.5M	9.8M	9.3M
Non-Current Liabilities
Long-term Debt i	16.3M	15.8M	2.3M	11.7M	11.0M
Deferred Tax Liabilities i	-	-	-	-	-
Other Non-Current Liabilities	-	68.0K	65.0K	-	1.0K
Total Non-Current Liabilities i	16.4M	15.8M	2.3M	11.7M	11.0M
Total Liabilities i	32.3M	26.2M	3.8M	21.5M	20.3M
Equity
Common Stock i	6.3M	4.8M	664.0K	8.4M	5.5M
Retained Earnings i	-34.9M	-5.7M	-7.2M	-73.1M	-61.6M
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	-22.7M	3.1M	-2.7M	3.3M	2.0M
Key Metrics
Total Debt i	28.2M	23.8M	3.5M	14.8M	13.7M
Working Capital i	-14.0M	-5.7M	-370.0K	9.0M	2.4M

Balance Sheet Composition

Biosenic SA Cash Flow Statement From 2019 to 2023

Metric	2023	2022	2021	2020	2019
Operating Activities
Net Income i	-7.0M	-2.3M	-877.0K	-17.4M	-11.2M
Depreciation & Amortization i	-	-	-	-	-
Stock-Based Compensation i	-	-	-99.0K	266.0K	-472.0K
Working Capital Changes i	55.0K	44.0K	10.0K	-1.0M	-5.0K
Operating Cash Flow i	-7.3M	-2.3M	-958.0K	-20.6M	-14.2M
Investing Activities
Capital Expenditures i	6.0K	-5.0K	0	-78.0K	-289.0K
Acquisitions i	0	2.0M	0	12.0M	0
Investment Purchases i	-	-	-	-	-
Investment Sales i	-	-	-	-	-
Investing Cash Flow i	6.0K	2.0M	0	11.9M	-289.0K
Financing Activities
Share Repurchases i	-	-	-	-	-
Dividends Paid i	-	-	-	-	-
Debt Issuance i	1.0M	1.0M	1.4M	10.3M	4.9M
Debt Repayment i	-413.0K	-424.0K	-181.0K	-6.6M	-1.2M
Financing Cash Flow i	2.1M	1.1M	1.2M	12.3M	11.6M
Free Cash Flow i	-3.5M	-1.9M	-1.1M	-16.2M	-10.7M
Net Change in Cash i	-5.2M	778.0K	252.0K	3.6M	-2.9M

Cash Flow Trend

Biosenic SA Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 0.00

Forward P/E -0.05

Price to Sales 0.61

PEG Ratio -0.05

Profitability Ratios

Profit Margin -279.17%

Operating Margin -17.33%

Return on Equity 126.75%

Return on Assets -22.77%

Financial Health

Current Ratio 0.40

Debt to Equity -1.31

Beta -2.43

Per Share Data

EPS (TTM) €-0.04

Book Value per Share €-0.08

Revenue per Share €0.02

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
bios	1.6M	0.00	-	126.75%	-279.17%	-1.31
Argenx SE	38.4B	37.82	6.33	24.72%	41.03%	0.71
UCB S.A	39.1B	29.72	4.00	14.30%	19.45%	29.72
European Medical	21.8M	44.15	2.35	5.40%	1.14%	191.98
Celyad Oncology S.A	13.4M	-0.17	25.00	-170.92%	0.00%	177.10
Onward Medical N.V	245.2M	-6.48	8.34	-167.80%	90.39%	54.33

Financial data is updated regularly. All figures are in the company's reporting currency.